Q4 2025 Management View CEO Dikla Akselbrad described 2025 as “a pivotal year for PolyPid,” highlighting the completion of ...

Candidates appearing for the Civil Services Examination (CSE) 2026 will get an opportunity to make changes to their ...

PolyPid (NASDAQ:PYPD) said 2025 marked a “pivotal year” as the company completed its SHIELD II Phase 3 trial and moved D-PLEX100 into the final stages of regulatory preparation, while also advancing U ...

The Company is in AdvancedStagesof Commercial U.S. Partnership Discussions for D-PLEX₁₀₀Positive FDA Pre-NDA Feedback Supports Rolling NDA ...

KalVista Pharmaceuticals, Inc. is rated a Strong Buy due to EKTERLY's global launch and robust initial sales momentum. Read ...

In an exclusive interview to The Quint, former UGC Chairman Sukhadeo Thorat weighs in on the new regulations, points out ...

Q4 2025 Earnings Call February 11, 2026 4:30 PM ESTCompany ParticipantsChad Fugure - Vice President of Investor ...

Thank you, operator, and thank you all for joining PolyPid's Fourth Quarter and Full Year 2025 Earnings Conference Call.

Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from ...

The trio of stars behind KPop Demon Hunters teased a potential sequel idea that would go much darker than Netflix's colossal global hit.

The table below is a review of notable updates that occurred in January 2026 for investigational products in development (not ...